Intranasal vaccination induced cross-protective secretory IgA antibodies against SARS-CoV-2 variants with reducing the potential risk of lung eosinophilic immunopathology

To control the coronavirus disease 2019 (COVID-19) pandemic, there is a need to develop vaccines to prevent infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants. One candidate is a nasal vaccine capable of inducing secretory IgA antibodies in the mucosa of the upper r...

Descripción completa

Detalles Bibliográficos
Autores principales: Hemmi, Takuya, Ainai, Akira, Hashiguchi, Takao, Tobiume, Minoru, Kanno, Takayuki, Iwata-Yoshikawa, Naoko, Iida, Shun, Sato, Yuko, Miyamoto, Sho, Ueno, Akira, Sano, Kaori, Saito, Shinji, Shiwa-Sudo, Nozomi, Nagata, Noriyo, Tamura, Koji, Suzuki, Ryosuke, Hasegawa, Hideki, Suzuki, Tadaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9439873/
https://www.ncbi.nlm.nih.gov/pubmed/36064667
http://dx.doi.org/10.1016/j.vaccine.2022.08.049

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9439873/
https://www.ncbi.nlm.nih.gov/pubmed/36064667
http://dx.doi.org/10.1016/j.vaccine.2022.08.049

Ejemplares similares